Volume 136, Issue 2, Pages (February 2015)

Slides:

Advertisements

Similar presentations

Fig. 1. Framework of developing a guideline for cervical cancer screening. ① Benefits of pap test screening, ② harms of pap test screening, ③ accuracy.

Advertisements

Volume 144, Issue 1, Pages (January 2017)

Volume 141, Issue 2, Pages (May 2016)

Retest in 12mo with HPV testing

Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade.

Volume 62, Issue 6, Pages (December 2012)

Volume 148, Issue 1, Pages (January 2018)

Prognostic value of human papillomavirus types 16 and 18 DNA physical status in cervical intraepithelial neoplasia A. Gradíssimo Oliveira, C. Delgado,

Volume 146, Issue 2, Pages (August 2017)

Akiko Mizukami, Toshihiko Kaise, PhD, Georges Van Kriekinge

Volume 149, Issue 3, Pages (June 2018)

Prognostic value of human papillomavirus types 16 and 18 DNA physical status in cervical intraepithelial neoplasia A. Gradíssimo Oliveira, C. Delgado,

Economic evaluation of vaccination: capturing the full benefits, with an application to human papillomavirus T. Bärnighausen, D.E. Bloom, E.T. Cafiero,

Volume 69, Issue 1, Pages (January 2016)

The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional.

Volume 150, Issue 1, Pages (July 2018)

The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional.

Are patients willing to travel for better ovarian cancer care?

Volume 148, Issue 1, Pages (January 2018)

Volume 148, Issue 1, Pages (January 2018)

Volume 146, Issue 3, Pages (September 2017)

Volume 138, Issue 1, Pages (July 2015)

Vulvar intraepithelial neoplasia: Risk factors for recurrence

Volume 149, Issue 6, Pages e1 (November 2015)

Volume 144, Issue 2, Pages (February 2017)

Patient-reported symptoms and performance status before palliative radiotherapy in geriatric cancer patients (octogenarians) Carsten Nieder, Thomas A.

Tracheal intubation by trainees does not alter the incidence or duration of postoperative sore throat and hoarseness: a teaching hospital-based propensity.

M. Ulm, D. Lee, A.R. Mabe, M.P. Lowe, S. Kumar, T. Tillmanns

Volume 151, Issue 1, Pages (October 2018)

Wilberto Nieves-Neira, J. Julie Kim, Daniela Matei

Supportive care plans: Linking patient-reported outcomes to evidence-based supportive care across the cancer continuum E.E. Stevens, J.N. Bottsford-Miller,

Volume 148, Issue 1, Pages (January 2018)

Volume 142, Issue 3, Pages (September 2016)

Pathologic response at interval debulking surgery following neoadjuvant chemotherapy predicts improved survival in women with ovarian cancer E.N. Prendergast,

K. Bixel, N. Denlinger, L. Marsh, A. Quick, R. Salani

Volume 152, Issue 1, Pages (January 2019)

Volume 152, Issue 1, Pages (January 2019)

Volume 143, Issue 2, Pages (November 2016)

Laparoscopic staging for stage I epithelial ovarian cancer: Analysis of the National Cancer Data Base A. Melamed, J.T. Clemmer, N.L. Keating, J.D. Wright,

The origins of multidisciplinary cancer care

Adherence to hematologic hold parameters in dose-dense chemotherapy for ovarian malignancies: A survey of the National Comprehensive Cancer Network (NCCN)

Comparing the health and economic impacts of cervical cancer screening strategies using the Cancer Risk Management Model (CRMM) C. Popadiuk, A.J. Coldman,

I. Mert, A. R. Munkarah, R. K. Hanna, J. Chhina, M. S. Carey, M

Volume 152, Issue 1, Pages (January 2019)

Are ovarian cancer debulking models reliable: Variance and predictability are dependent on institutional optimal debulking rates N.A. Latif, E.M. Ko,

Volume 130, Issue 1, Pages (July 2013)

HPV vaccines – A review of the first decade

Volume 147, Issue 1, Pages (October 2017)

Cervical excisional treatment of young women: A population-based study

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Limited access safety lead-in of the MEK inhibitor trametinib in combination with GSK , an AKT inhibitor, in patients with recurrent or persistent.

Volume 153, Issue 1, Pages (April 2019)

Volume 130, Issue 3, Pages (September 2013)

The complex interaction of cancer surgery, complications, and patient-reported outcomes: A single score is not enough K.M. Doll, E.L. Barber, J.T. Bensen,

Volume 142, Issue 2, Pages (August 2016)

Annika Idahl, Andrea Hermansson, Ann Lalos Gynecologic Oncology

Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis Chunqing Lin,

Urine-Based HPV Testing as a Method to Screen for Cervical Cancer

Volume 152, Issue 1, Pages (January 2019)

Volume 130, Issue 1, Pages (July 2013)

Volume 153, Issue 1, Pages (April 2019)

The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled.

Volume 120, Issue 4, Pages (March 2001)

Should ovarian preservation be considered for women younger than 60 years with endometrial carcinoma? L.M. Bean, K. Taylor, K.M. Anderson, M.A. Davis,

Volume 115, Issue 1, Pages (October 2009)

Volume 153, Issue 3, Pages (June 2019)

Fig. 3. The examinations consumed by the three cervical screening strategies to detect CIN2+/CIN3+. (A) The cases of CIN2+ detected by three current cervical.

Fig. 2. Three cervical screening strategies to detect CIN2+/CIN3+

Fig. 1. Flowchart of inclusion and exclusion criteria of the study population.ASC-US, atypical squamous cells of undetermined significance; CIN, cervical.

Volume 154, Issue 1, Pages (July 2019)

Presentation transcript:

Volume 136, Issue 2, Pages 189-197 (February 2015) Primary cervical cancer screening with human papillomavirus: End of study results from the ATHENA study using HPV as the first-line screening test Thomas C. Wright, Mark H. Stoler, Catherine M. Behrens, Abha Sharma, Guili Zhang, Teresa L. Wright Gynecologic Oncology Volume 136, Issue 2, Pages 189-197 (February 2015) DOI: 10.1016/j.ygyno.2014.11.076 Copyright © 2014 The Authors Terms and Conditions

Fig. 1 A: CONSORT Diagram of flow of patients through the study. B: CONSORT Diagram showing at what point patients were diagnosed with CIN2+. Gynecologic Oncology 2015 136, 189-197DOI: (10.1016/j.ygyno.2014.11.076) Copyright © 2014 The Authors Terms and Conditions

Fig. 1 A: CONSORT Diagram of flow of patients through the study. B: CONSORT Diagram showing at what point patients were diagnosed with CIN2+. Gynecologic Oncology 2015 136, 189-197DOI: (10.1016/j.ygyno.2014.11.076) Copyright © 2014 The Authors Terms and Conditions

Fig. 2 Verification bias-adjusted (VBA) cumulative incidence of consensus pathology cervical intraepithelial neoplasia 2+ (CIN2+) (A) and CIN3+ (B) during 3years of follow-up stratified by baseline human papillomavirus (HPV) status. Red solid line, HPV-16 positive; blue solid line, HPV-18 positive; green solid line, 12 other HPV genotypes positive; black dotted line, HPV-negative. Gynecologic Oncology 2015 136, 189-197DOI: (10.1016/j.ygyno.2014.11.076) Copyright © 2014 The Authors Terms and Conditions

Fig. 3 Verification bias-adjusted (VBA) 3-year cumulative incidence rates of consensus pathology cervical intraepithelial neoplasia 2+ (CIN2+) and CIN3+ stratified by different combinations of baseline cervical cytology and HPV results. Note the x-axis is logarithmic. Gynecologic Oncology 2015 136, 189-197DOI: (10.1016/j.ygyno.2014.11.076) Copyright © 2014 The Authors Terms and Conditions